Akoya Biosciences Inc

NASDAQ AKYA

Download Data

Akoya Biosciences Inc Price to Free Cash Flow to Firm Ratio (P/FCFF) on June 03, 2024: -2.18

Akoya Biosciences Inc Price to Free Cash Flow to Firm Ratio (P/FCFF) is -2.18 on June 03, 2024, a 41.45% change year over year. The price to free cash flow to the firm (FCFF) ratio compares the market price per share of a company's stock to its free cash flow available to the firm. It is calculated by dividing the market capitalization by the sum of the free cash flow plus the interest expense multiplied by (1 - tax rate), divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's FCFF generation. A higher ratio suggests that investors are willing to pay a higher price for each unit of free cash flow available to the firm, indicating positive market sentiment.
  • Akoya Biosciences Inc 52-week high Price to Free Cash Flow to Firm Ratio (P/FCFF) is -2.07 on May 23, 2024, which is 4.90% above the current Price to Free Cash Flow to Firm Ratio (P/FCFF).
  • Akoya Biosciences Inc 52-week low Price to Free Cash Flow to Firm Ratio (P/FCFF) is -6.29 on March 01, 2024, which is -188.97% below the current Price to Free Cash Flow to Firm Ratio (P/FCFF).
  • Akoya Biosciences Inc average Price to Free Cash Flow to Firm Ratio (P/FCFF) for the last 52 weeks is -4.21.
NASDAQ: AKYA

Akoya Biosciences Inc

CEO Mr. Brian McKelligon
IPO Date April 16, 2021
Location United States
Headquarters 100 Campus Drive, Marlborough, MA, United States, 01752
Employees 330
Sector Healthcare
Industry Medical instruments & supplies
Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

PDEX

Pro-Dex Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email